Drugs.com - Pharma Industry News

ASCO: Maintenance Lurbinectedin + Atezolizumab Enhances Survival in Lung Cancer

TUESDAY, May 27, 2025 -- Maintenance therapy with lurbinectedin (lurbi) and atezolizumab (atezo) helps some patients with extensive-stage small cell lung cancer (ES-SCLC) live longer versus maintenance therapy with atezolizumab alone, according to...

May 27, 2025 - 18:50
 0
ASCO: Maintenance Lurbinectedin + Atezolizumab Enhances Survival in Lung Cancer
TUESDAY, May 27, 2025 -- Maintenance therapy with lurbinectedin (lurbi) and atezolizumab (atezo) helps some patients with extensive-stage small cell lung cancer (ES-SCLC) live longer versus maintenance therapy with atezolizumab alone, according to...
Read More

Tags:

Previous Article

ASCO: Alcohol-Associated Cancer Mortality Increased From 1990 to 2021

Next Article

Replacing Sedentary Activity With Sleep, Exercise Beneficial in Acute Coronary S...

Related Posts

Prevalence of Disability Up Over Twofold for Current Smokers

Prevalence of Disability Up Over Twofold for Current Sm...

May 30, 2025  0

Calorie Restrictions, Low-Fat Diets May Reduce Depressive Symptoms

Calorie Restrictions, Low-Fat Diets May Reduce Depressi...

May 20, 2025  0

Earlier Natural Menopause Risk Increased for Women in Socially Vulnerable Neighborhoods

Earlier Natural Menopause Risk Increased for Women in S...

May 29, 2025  0